Xickle® RBC-Plus™ is available now. WHY WAIT. Live a Healthier Life!
Connect With Us


  1. Research Preview on Improving Nicosan/Xickle

    February 16, 2015 by Andrea
    Photo by U.S. Army photo by Sgt. 1st Class Roddy Rieger via Creative Commons Attribution 2.0 Generic

    Photo by U.S. Army photo by Sgt. 1st Class Roddy Rieger via Creative Commons Attribution 2.0 Generic (Illustrative Purposes Only)

    No sickler should have to suffer. 

    This is why we -- the Xickle team -- are dedicated not only to raising awareness about SCD, but also to developing products that can benefit sickle cell warriors of all ages. Most recently, we've begun our very own clinical trial in order to further our goal of receiving FDA-approval for Xickle RBC-Plus as a treatment for SCD. It may take up to seven years to receive such FDA approval. In the meantime, we are allowed to offer Xickle RBC-Plus as a supplement. We understand that people with SCD are bombarded with information about new drugs and supplements regularly, so to help you understand how Xickle RBC-Plus differs from other products you may have heard about, we'll be breaking things down in more detail below.  

    Basically, Xickle is an improved formulation of Nicosan (Nicosan/Niprisan was approved for the treatment of SCD in Nigeria) and is made up of the extracts from dried plants, one of them being sorghum bicolor leaves. It turns out, certain sorghum extracts have powerful anti-sickling activity.  

    During our research and development, we collected sorghum seeds from 19 countries, studied their germination, growth, and ability to respond to being mixed with different compounds thought to help encourage the anti-sickling property. Those seeds were then planted, harvested monthly, and analyzed. This research resulted in increased potency of the product, as well as advanced methods of standardizing the way the product is made. These strides will allow us to efficiently mass produce Xickle. This research is a big step forward in helping us reach our FDA-approval goals.

    Read this and this, too, for even more information on our research and tell us your thoughts in the comments below!

  2. Xickle RBC-Plus: The Next Generation of Niprisan

    January 19, 2015 by Andrea

    Remember Niprisan, the drug that was approved for the treatment of sickle cell in Nigeria? See the results from the Niprisan clinical trial in the graph below. Well, Xickle RBC-Plus is the new generation of Niprisan. Currently sold in its supplement form, Xickle RBC-Plus has shown that it can help prevent the red blood cells of sickle cell patients from sickling. Clinical trials are currently underway.

    Niprasan vs Control

    Before preparing for our human clinical trials, we tested Xickle RBC-Plus on mice with human sickle cell disease. The mice that were given Xickle RBC-Plus lived longer, healthier lives than the mice who were not given the supplement. Take a look at the photo below to see just how our supplement helped maintain the shape of the red blood cells in the treated mice.

    Mice RBCs

    This next image, shows the same supplement at work of the blood from a person with sickle cell disease. The cells on the left were taken from a sickle cell patient and put under low oxygen conditions, as expected, they sickled. The cells on the right were also drawn from a sickle cell patient and subjected to low oxygen conditions, but this time, Xickle RBC-Plus was added to the blood. As you can see, it helped keep them from becoming sickled.


    In the next few weeks and months, we'll be presenting you with more updates about our clinical trial and its progress. Meanwhile, stay up to date by following us on Facebook and Twitter. Have any questions? Comment below or Tweet us @XickleRBC!

Sign Up For Xickle's Newsletter!

Get the latest news, health tips and special offers!

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!